Movement Alert｜BeOne Medicines Rises 3.35% in Regular Trading, Brukinsa Phase 3 Positive Data and Sector Rally Lift Shares

Market Focus07-02

On July 2, BeOne Medicines (06160.HK) rose 3.35% in regular trading, trading at HK$175.2/share, with turnover of HK$535 million. The stock was supported by a dual catalyst of key clinical data and broad sector strength.

On the news front, the company announced on June 30 that Brukinsa (zanubrutinib) achieved positive results in the Phase 3 MANGROVE study evaluating the BTK inhibitor combined with rituximab versus bendamustine plus rituximab for first-line treatment of adult mantle cell lymphoma (MCL). The study met its primary endpoint of progression-free survival, demonstrating a 43% reduction in disease progression or death risk (HR=0.57; p<0.0001). This is the first Phase 3 study to advance a chemotherapy-free standard in first-line MCL treatment. The company plans to file for global regulatory approval in the second half of the year.

Meanwhile, the biotech sector rallied broadly, with 3SBIO up 10.6%, AKESO up 8.8%, SKB BIO up 8.57%, and INNOVENT BIO up 8.04%, providing additional momentum. A prior short-term headwind from a RMB 446 million tax supplementary payment disclosed on June 26 has been largely absorbed by the market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136788998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136788998","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BeOne Medicines Rises 3.35% in Regular Trading, Brukinsa Phase 3 Positive Data and Sector Rally Lift Shares","media":"Market Focus","content":"<p><p>On July 2, BeOne Medicines (06160.HK) rose 3.35% in regular trading, trading at HK$175.2/share, with turnover of HK$535 million. The stock was supported by a dual catalyst of key clinical data and broad sector strength.</p><p>On the news front, the company announced on June 30 that Brukinsa (zanubrutinib) achieved positive results in the Phase 3 MANGROVE study evaluating the BTK inhibitor combined with rituximab versus bendamustine plus rituximab for first-line treatment of adult mantle cell lymphoma (MCL). The study met its primary endpoint of progression-free survival, demonstrating a 43% reduction in disease progression or death risk (HR=0.57; p&lt;0.0001). This is the first Phase 3 study to advance a chemotherapy-free standard in first-line MCL treatment. The company plans to file for global regulatory approval in the second half of the year.</p><p>Meanwhile, the biotech sector rallied broadly, with 3SBIO up 10.6%, AKESO up 8.8%, SKB BIO up 8.57%, and INNOVENT BIO up 8.04%, providing additional momentum. A prior short-term headwind from a RMB 446 million tax supplementary payment disclosed on June 26 has been largely absorbed by the market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeOne Medicines Rises 3.35% in Regular Trading, Brukinsa Phase 3 Positive Data and Sector Rally Lift Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeOne Medicines Rises 3.35% in Regular Trading, Brukinsa Phase 3 Positive Data and Sector Rally Lift Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 10:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, BeOne Medicines (06160.HK) rose 3.35% in regular trading, trading at HK$175.2/share, with turnover of HK$535 million. The stock was supported by a dual catalyst of key clinical data and broad sector strength.</p><p>On the news front, the company announced on June 30 that Brukinsa (zanubrutinib) achieved positive results in the Phase 3 MANGROVE study evaluating the BTK inhibitor combined with rituximab versus bendamustine plus rituximab for first-line treatment of adult mantle cell lymphoma (MCL). The study met its primary endpoint of progression-free survival, demonstrating a 43% reduction in disease progression or death risk (HR=0.57; p&lt;0.0001). This is the first Phase 3 study to advance a chemotherapy-free standard in first-line MCL treatment. The company plans to file for global regulatory approval in the second half of the year.</p><p>Meanwhile, the biotech sector rallied broadly, with 3SBIO up 10.6%, AKESO up 8.8%, SKB BIO up 8.57%, and INNOVENT BIO up 8.04%, providing additional momentum. A prior short-term headwind from a RMB 446 million tax supplementary payment disclosed on June 26 has been largely absorbed by the market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1136788998","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136788998","pubTimestamp":1782958881,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, BeOne Medicines (06160.HK) rose 3.35% in regular trading, trading at HK$175.2/share, with turnover of HK$535 million. The stock was supported by a dual catalyst of key clinical data and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势警报|BeOne Medicines常规交易上涨3.35%，Brukinsa第三阶段利好数据和板块反弹提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On July 2, BeOne Medicines (06160.HK) rose 3.35% in regular trading, trading at HK$175.2/share, with turnover of HK$535 million. The stock was supported by a dual catalyst of key clinical data and broad sector strength.On the news front, the company announced on June 30 that Brukinsa (zanubrutinib) achieved positive results in the Phase 3 MANGROVE study evaluating the BTK inhibitor combined with rituximab versus bendamustine plus rituximab for first-line treatment of adult mantle cell lymphoma (MCL). The study met its primary endpoint of progression-free survival, demonstrating a 43% reduction in disease progression or death risk (HR=0.57; p<0.0001). This is the first Phase 3 study to advance a chemotherapy-free standard in first-line MCL treatment. The company plans to file for global regulatory approval in the second half of the year.Meanwhile, the biotech sector rallied broadly, with 3SBIO up 10.6%, AKESO up 8.8%, SKB BIO up 8.57%, and INNOVENT BIO up 8.04%, providing additional momentum. A prior short-term headwind from a RMB 446 million tax supplementary payment disclosed on June 26 has been largely absorbed by the market.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136788998","isCrawlerRequest":true}